title: Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
abstract: OBJECTIVE
  Pharmacologic treatment of lower urinary tract symptoms from benign prostatic hyperplasia (BPH) commonly includes alpha-blockers (ABs) and 5alpha-reductase inhibitors (5ARIs). Many clinicians use ABs for rapid symptom control and 5ARIs to modify long-term disease progression. The purpose of this study was to assess the clinical impact of delayed 5ARI therapy in patients treated with AB for lower urinary tract symptoms.
  
  
  METHODS
  Using two nationally representative databases, two retrospective analyses were conducted including patients aged > or =50 years treated for BPH between 2000 and 2007. Clinical outcomes for those using add-on 5ARI therapy early (within 30 days of initiating AB) and late (>30 days after initiating AB) were compared. Likelihood of clinical progression, defined as the presence of acute urinary retention (AUR) and prostate surgery, was assessed over 1 year after AB initiation, and modeled as a function of the treatment cohorts and the following baseline covariates: AUR, BPH stage, Charlson Comorbidity Index, age, and number of unique diagnosis codes, unique non-BPH-related classes of prescriptions filled, and specialty care.
  
  
  RESULTS
  Of 6896 men included in the analyses, approximately 60% initiated 5ARI therapy within 30 days of AB therapy (the early cohort). Patients in the early cohort were less likely to have clinical progression. Each 30-day delay in starting 5ARIs resulted in an increased likelihood of overall clinical progression (average 21.1%), AUR (average 18.6%), and prostate-related surgery (average 26.7%).
  
  
  CONCLUSIONS
  These results suggest that delaying 5ARI therapy in men with BPH increases the risk of AUR and prostate surgery.
  
  
  CONCLUSIONS
  Confounding factors, such as symptom severity and prostate volume, may have influenced the findings of the study.
authors.affiliation: University of Maryland School of Medicine, 29 S. Greene Street, Baltimore, MD 21201, USA. MNASLUND@smail.umaryland.edu
authors.forename: Michael
authors.initials: M
authors.lastname: Naslund
authors.forename: Michael T
authors.initials: MT
authors.lastname: Eaddy
authors.forename: Susan L
authors.initials: SL
authors.lastname: Hogue
authors.forename: Eric J
authors.initials: EJ
authors.lastname: Kruep
authors.forename: Manan B
authors.initials: MB
authors.lastname: Shah
mesh_terms: D058891:5-alpha Reductase Inhibitors; D000208:Acute Disease; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000368:Aged; D000369:Aged, 80 and over; D018450:Disease Progression; D004334:Drug Administration Schedule; D004791:Enzyme Inhibitors / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011468:Prostatectomy / Q000009:adverse effects / Q000534:rehabilitation; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy* / Q000601:surgery; D012189:Retrospective Studies; D013997:Time Factors; D016055:Urinary Retention / Q000175:diagnosis* / Q000209:etiology
chemical_list: D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists; D004791:Enzyme Inhibitors